Dallas TX 三阴性乳腺癌临床试验
18项针对 三阴性乳腺癌的研究正在 Dallas及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本（英文）
正在为研究招募参与者？将此页面置顶展示 — $99 / 30天 →
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
招募中1/2 期
- UT Southwest Simmons Cancer Center, Dallas
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
招募中1 期
- UT Southwestern, Dallas
Study of AVZO-021 in Patients With Advanced Solid Tumors
招募中1/2 期
- Avenzo Therapeutics Recruiting Site, Dallas
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
招募中3 期
- Texas Oncology - DFW ( Site 8007), Dallas
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
招募中3 期
- Texas Oncology - DFW ( Site 8000), Dallas
- Parkland Health & Hospital System ( Site 0096), Dallas
- University of Texas Southwestern Medical Center ( Site 0032), Dallas
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
招募中3 期
- Texas Oncology - DFW ( Site 8009), Dallas
- UT Southwestern ( Site 0092), Dallas
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
招募中1 期
- University of Texas Southwestern Medical Center, Dallas
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
招募中1 期
- Normunity Investigational Site, Dallas
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
招募中1/2 期
- Mary Crowley Cancer Research, Dallas
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
招募中1 期
- University of Texas Southwestern Medical Center - Simmons Cancer Center, Dallas
- UT Southwestern Medical Center - Redbird, Dallas
- Univ. of TX Southwestern Medical Center - Zale Lipshy University Hospital, Dallas
- 以及另外 2 项
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
招募中1/2 期
- Texas Oncology, P.A., Dallas
Study of XB010 in Subjects With Solid Tumors
招募中1 期
- Baylor University Medical Center, Dallas
BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia
招募中1 期
- Baylor University Medical Center, Dallas
A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer
招募中1/2 期
- Texas Oncology - DFW, Dallas
JAB-2485 Activity in Adult Patients With Advanced Solid Tumors
招募中1/2 期
- Mary Crowley Cancer Research, Dallas
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
招募中1 期
- Dren Investigational Site, Dallas
Neratinib in Combination With Ruxolitinib in Patients With mTNBC
招募中早期 I 期
- Baylor University Medical Center, Baylor Charles A Sammons Cancer Center, Dallas
A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors
招募中1 期
- NEXT Oncology, Dallas, Dallas
其他城市的 三阴性乳腺癌试验
- Houston, TX42 项研究
- New York City, NY31 项研究
- Nashville, TN28 项研究
- Los Angeles, CA27 项研究
- Boston, MA26 项研究
- San Antonio, TX23 项研究
- St. Louis, MO21 项研究
- Arlington, VA20 项研究
- Atlanta, GA20 项研究
- Chicago, IL16 项研究
- Columbus, OH16 项研究
- Grand Rapids, MI15 项研究
Dallas的其他研究
- 乳腺癌55 项研究
- 非小细胞肺癌52 项研究
- 转移性癌症42 项研究
- 心力衰竭42 项研究
- 癌症（所有类型）37 项研究
- 前列腺癌36 项研究
- 结直肠癌33 项研究
- 肥胖症30 项研究
- 卵巢癌28 项研究
- 肺癌27 项研究
- 膀胱癌27 项研究
- 子宫内膜癌24 项研究
数据来自 ClinicalTrials.gov，检索日期：2026年10月6日。每项研究自行设定入选标准，由研究团队决定谁能参与。